← All trials
NCT05295173
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 21, 2022
- Primary completion
- May 31, 2023
- Completion date
- May 31, 2023
- First posted
- Mar 25, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 1412
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Angde Biotech Pharmaceutical Co., Ltd.Lead sponsor
- Capital Medical UniversityCollaborator
- Capital Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.